Clinical Trials Sponsored by Ludwig Institute for Cancer Research

Total 10680 results

Ludwig Institute for Cancer Research

Completed

Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer

Prostate Cancer

Switzerland, Germany
Ludwig Institute for Cancer Research

Completed

Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

Switzerland, Germany
Ludwig Institute for Cancer Research

Completed

111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen

Neoplasms

Australia
Ludwig Institute for Cancer Research

Terminated

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Malignant Melanoma

Belgium
Ludwig Institute for Cancer Research

Completed

A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.

Cancer | Neoplasm

Germany
Ludwig Institute for Cancer Research

Terminated

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Malignant Melanoma

Belgium
Ludwig Institute for Cancer Research

Completed

Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1

Neoplasms

Japan
Ludwig Institute for Cancer Research

Terminated

Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Ludwig Institute for Cancer Research
AstraZeneca

Completed

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Esophageal Cancer

United Kingdom
Ludwig Institute for Cancer Research
Medarex

Terminated

A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Synovial Sarcoma

United States
Ludwig Institute for Cancer Research
AgonOx

Withdrawn

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma

Metastatic Melanoma
Ludwig Institute for Cancer Research
Cancer Research Institute (CRI)

Completed

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

Malignant Melanoma

United States
Ludwig Institute for Cancer Research
Krankenhaus Nordwest

Completed

A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen

Melanoma | Sarcoma | Breast Cancer | Head and Neck Cancer | Esophageal Cancer | Transitional Cell Carcinoma | Prostate Cancer | Ovarian Carcinoma | Gastrointestinal Stromal Tumor (GIST)

Germany
Ludwig Institute for Cancer Research
Mie University

Completed

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

Stomach Cancer | Breast Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer

Japan
Ludwig Institute for Cancer Research
Cancer Research Institute, NY, USA

Terminated

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Unresectable or Metastatic Melanoma

United States, Australia
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Terminated

Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer

Ovarian Cancer

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

Australia
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer

Ovarian Cancer

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)

Lung Cancer

United States
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute

Completed

Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Kidney Cancer

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Transitional Cell Carcinoma

United States
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center

Completed

Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center

Completed

Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250

Kidney Cancer | Renal Cell Carcinoma | Renal Cancer | Kidney Neoplasm

United States
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center

Completed

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

Kidney Cancer | Clear Cell Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Neoplasms | Cancer of Kidney | Neoplasms, Kidney

United States
Ludwig Institute for Cancer Research
Radboud University Medical Center

Completed

Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer

Metastatic Renal Cell Carcinoma

Netherlands
Memorial Sloan Kettering Cancer Center
Ludwig Institute for Cancer Research

Active, not recruiting

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Tumor | COlorectal Carcinoma

United States
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Melanoma

United Kingdom, Australia, New Zealand
Ludwig Institute for Cancer Research
Bristol-Myers Squibb

Terminated

Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

Metastatic Melanoma

Australia
Ludwig Institute for Cancer Research
Daiichi Sankyo, Inc.

Completed

A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

Australia
Ludwig Institute for Cancer Research
NYU Langone Health

Completed

NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

Tumors

United States
NYU Langone Health
Ludwig Institute for Cancer Research

Terminated

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

Cutaneous T-cell Lymphoma

United States
Ludwig Institute for Cancer Research
Johns Hopkins University

Withdrawn

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Solid Tumors | Lymphomas

Germany
Ludwig Institute for Cancer Research
Austin Health; Peter MacCallum Cancer Institute

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma

Melanoma

Australia
Ludwig Institute for Cancer Research
Pfizer; Heidelberg Pharma AG

Terminated

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma (RCC)

Australia
Centre Hospitalier Universitaire Vaudois
Ludwig Institute for Cancer Research

Completed

Immunotherapy of Stage III/IV Melanoma Patients

Melanoma

Switzerland
Centre Hospitalier Universitaire Vaudois
Ludwig Institute for Cancer Research

Completed

Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients

Melanoma

Switzerland
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Melanoma | Sarcoma | Breast Cancer | Solid Tumor | Prostate Cancer | Bladder Cancer | Head and Neck Squamous Cell Carcinoma | Cutaneous T-Cell Lymphoma | Renal Cancer | Merkel Cell Carcinoma | Testicular Cancer

United States
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute; New York University Cancer Institute

Completed

Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Ludwig Institute for Cancer Research
Celgene; Cancer Research Institute, New York City; MedImmune LLC

Completed

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Ovarian Cancer

United States, Switzerland
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center; NYU Langone Health

Completed

Study of ADI-PEG 20 in Patients With Advanced Melanoma

Skin Cancer | Metastatic Melanoma | Neoplasm

United States
Ludwig Institute for Cancer Research
Bristol-Myers Squibb; Conquer Cancer Foundation

Completed

Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Otsuka America Pharmaceutical; Ludwig Institute for Cancer Research

Completed

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

Multiple Myeloma

United States
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC; Targovax ASA

Completed

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Colorectal Cancer | Ovarian Cancer | Appendiceal Cancer

United States
Ludwig Institute for Cancer Research
Daiichi Sankyo Co., Ltd.; Austin Health

Completed

Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers (LUD2014-002)

Malignant Solid Tumor | Metastatic EphA2 Positive Cancer

Australia
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC; Multiple Myeloma Research...

Terminated

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Multiple Myeloma

United States
Ludwig Institute for Cancer Research
Boehringer Ingelheim; MedImmune LLC; PharmaJet, Inc.; CureVac; Cancer Research Institute...

Completed

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NSCLC | Metastatic Non-small Cell Lung Cancer

United States
Ludwig Boltzmann Institute for Lung Health

Completed

CoVid-19 - Infection and Antibody Formation in the Viennese Population

Virus Diseases | COVID-19

Austria

Clinical Trials Sponsored by Ludwig Institute for Cancer Research

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations